148 related articles for article (PubMed ID: 23642333)
1. Antiplatelet therapy and cardiac surgery: review of recent evidence and clinical implications.
Fitchett D; Mazer CD; Eikelboom J; Verma S
Can J Cardiol; 2013 Sep; 29(9):1042-7. PubMed ID: 23642333
[TBL] [Abstract][Full Text] [Related]
2. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
Alexopoulos D; Goudevenos JA; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Parissis H; Ntalas IV; Angelidis C; Petousis S; Vavuranakis M; Hahalis G; Stefanadis C;
Int J Cardiol; 2013 Oct; 168(6):5329-35. PubMed ID: 23978364
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.
Wouter Jukema J; Collet JP; De Luca L
Curr Med Res Opin; 2012 Feb; 28(2):203-11. PubMed ID: 22181345
[TBL] [Abstract][Full Text] [Related]
4. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Tanguay JF; Bell AD; Ackman ML; Bauer RD; Cartier R; Chan WS; Douketis J; Roussin A; Schnell G; Verma S; Wong G; Mehta SR;
Can J Cardiol; 2013 Nov; 29(11):1334-45. PubMed ID: 23978596
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet options for secondary prevention in acute coronary syndromes.
Silvain J; Cayla G; O'Connor SA; Collet JP; Montalescot G
Expert Rev Cardiovasc Ther; 2011 Nov; 9(11):1403-15. PubMed ID: 22059790
[TBL] [Abstract][Full Text] [Related]
6. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
7. Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.
Price MJ; Walder JS; Baker BA; Heiselman DE; Jakubowski JA; Logan DK; Winters KJ; Li W; Angiolillo DJ
J Am Coll Cardiol; 2012 Jun; 59(25):2338-43. PubMed ID: 22698488
[TBL] [Abstract][Full Text] [Related]
8. Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
Med Lett Drugs Ther; 2011 Sep; 53(1372):69-70. PubMed ID: 21897348
[TBL] [Abstract][Full Text] [Related]
9. Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation.
Huang PH; Croce KJ; Bhatt DL; Resnic FS
Crit Pathw Cardiol; 2012 Dec; 11(4):177-85. PubMed ID: 23149359
[TBL] [Abstract][Full Text] [Related]
10. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
Steiner S; Moertl D; Chen L; Coyle D; Wells GA
Thromb Haemost; 2012 Aug; 108(2):318-27. PubMed ID: 22627948
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor: a novel reversible oral antiplatelet agent.
Nawarskas JJ; Clark SM
Cardiol Rev; 2011; 19(2):95-100. PubMed ID: 21285670
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
[TBL] [Abstract][Full Text] [Related]
13. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
Packard KA; Campbell JA; Knezevich JT; Davis EM
Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
[TBL] [Abstract][Full Text] [Related]
14. Dyspnea and reversibility of antiplatelet agents: ticagrelor, elinogrel, cangrelor, and beyond.
Serebruany VL; Sibbing D; DiNicolantonio JJ
Cardiology; 2014; 127(1):20-4. PubMed ID: 24192670
[TBL] [Abstract][Full Text] [Related]
15. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
[TBL] [Abstract][Full Text] [Related]
16. New anti-platelet agents: the end of resistance?
Kastrati A
Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
[TBL] [Abstract][Full Text] [Related]
17. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
[TBL] [Abstract][Full Text] [Related]
18. ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly.
Oprea AD; Popescu WM
J Cardiothorac Vasc Anesth; 2013 Aug; 27(4):779-95. PubMed ID: 23648080
[No Abstract] [Full Text] [Related]
19. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Coleman CI; Limone BL
Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
[TBL] [Abstract][Full Text] [Related]
20. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
Varenhorst C; Alström U; Scirica BM; Hogue CW; Åsenblad N; Storey RF; Steg PG; Horrow J; Mahaffey KW; Becker RC; James S; Cannon CP; Brandrup-Wognsen G; Wallentin L; Held C
J Am Coll Cardiol; 2012 Oct; 60(17):1623-30. PubMed ID: 23021325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
